VaxcineTM: an oil-based adjuvant for influenza vaccines
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2011 |
| Outros Autores: | , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Memórias do Instituto Oswaldo Cruz |
| Texto Completo: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000800026 |
Resumo: | Vaccination is the method of choice for the prevention of influenza infection. However, the quantity of the antigen available, especially in the case of pandemics, often fails to meet the global demand. However, improved adjuvants can overcome this problem. Preliminary results obtained in this study revealed that one year after a single subcutaneous immunisation with influenza A H3N2 virus in an oil-based carrier, VaxcineTM, outbreed mice produced a high immunoglobulin G response that lasted for up to one year and exhibited less variation in titre compared with the response of the control group treated with alum. The haemagglutination-inhibition titres induced by VaxcineTM were also higher than those generated by alum. These data indicate that VaxcineTM is a good adjuvant candidate for seasonal influenza vaccines. |
| id |
FIOCRUZ-4_50c7b6dcf3119d2dcaaee8c420f7ee66 |
|---|---|
| oai_identifier_str |
oai:scielo:S0074-02762011000800026 |
| network_acronym_str |
FIOCRUZ-4 |
| network_name_str |
Memórias do Instituto Oswaldo Cruz |
| spelling |
VaxcineTM: an oil-based adjuvant for influenza vaccinesVaxcineTMadjuvantinfluenzavaccineVaccination is the method of choice for the prevention of influenza infection. However, the quantity of the antigen available, especially in the case of pandemics, often fails to meet the global demand. However, improved adjuvants can overcome this problem. Preliminary results obtained in this study revealed that one year after a single subcutaneous immunisation with influenza A H3N2 virus in an oil-based carrier, VaxcineTM, outbreed mice produced a high immunoglobulin G response that lasted for up to one year and exhibited less variation in titre compared with the response of the control group treated with alum. The haemagglutination-inhibition titres induced by VaxcineTM were also higher than those generated by alum. These data indicate that VaxcineTM is a good adjuvant candidate for seasonal influenza vaccines.Instituto Oswaldo Cruz, Ministério da Saúde2011-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000800026Memórias do Instituto Oswaldo Cruz v.106 n.8 2011reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/S0074-02762011000800026info:eu-repo/semantics/openAccessAlves,Rosely Cabette BarbosaNew,Roger Randal CharlesAndrade,Gabrielle RibeiroMendonça,Rita Maria ZucatelliSant'Anna,Osvaldo Augusto Brasil EstevesMancini,Dalva Assunção PortariSilva-Junior,Silvio Marciano daDomingos,Marta de Oliveiraeng2020-04-25T17:51:05Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:18:00.861Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue |
| dc.title.none.fl_str_mv |
VaxcineTM: an oil-based adjuvant for influenza vaccines |
| title |
VaxcineTM: an oil-based adjuvant for influenza vaccines |
| spellingShingle |
VaxcineTM: an oil-based adjuvant for influenza vaccines Alves,Rosely Cabette Barbosa VaxcineTM adjuvant influenza vaccine |
| title_short |
VaxcineTM: an oil-based adjuvant for influenza vaccines |
| title_full |
VaxcineTM: an oil-based adjuvant for influenza vaccines |
| title_fullStr |
VaxcineTM: an oil-based adjuvant for influenza vaccines |
| title_full_unstemmed |
VaxcineTM: an oil-based adjuvant for influenza vaccines |
| title_sort |
VaxcineTM: an oil-based adjuvant for influenza vaccines |
| author |
Alves,Rosely Cabette Barbosa |
| author_facet |
Alves,Rosely Cabette Barbosa New,Roger Randal Charles Andrade,Gabrielle Ribeiro Mendonça,Rita Maria Zucatelli Sant'Anna,Osvaldo Augusto Brasil Esteves Mancini,Dalva Assunção Portari Silva-Junior,Silvio Marciano da Domingos,Marta de Oliveira |
| author_role |
author |
| author2 |
New,Roger Randal Charles Andrade,Gabrielle Ribeiro Mendonça,Rita Maria Zucatelli Sant'Anna,Osvaldo Augusto Brasil Esteves Mancini,Dalva Assunção Portari Silva-Junior,Silvio Marciano da Domingos,Marta de Oliveira |
| author2_role |
author author author author author author author |
| dc.contributor.author.fl_str_mv |
Alves,Rosely Cabette Barbosa New,Roger Randal Charles Andrade,Gabrielle Ribeiro Mendonça,Rita Maria Zucatelli Sant'Anna,Osvaldo Augusto Brasil Esteves Mancini,Dalva Assunção Portari Silva-Junior,Silvio Marciano da Domingos,Marta de Oliveira |
| dc.subject.por.fl_str_mv |
VaxcineTM adjuvant influenza vaccine |
| topic |
VaxcineTM adjuvant influenza vaccine |
| dc.description.none.fl_txt_mv |
Vaccination is the method of choice for the prevention of influenza infection. However, the quantity of the antigen available, especially in the case of pandemics, often fails to meet the global demand. However, improved adjuvants can overcome this problem. Preliminary results obtained in this study revealed that one year after a single subcutaneous immunisation with influenza A H3N2 virus in an oil-based carrier, VaxcineTM, outbreed mice produced a high immunoglobulin G response that lasted for up to one year and exhibited less variation in titre compared with the response of the control group treated with alum. The haemagglutination-inhibition titres induced by VaxcineTM were also higher than those generated by alum. These data indicate that VaxcineTM is a good adjuvant candidate for seasonal influenza vaccines. |
| description |
Vaccination is the method of choice for the prevention of influenza infection. However, the quantity of the antigen available, especially in the case of pandemics, often fails to meet the global demand. However, improved adjuvants can overcome this problem. Preliminary results obtained in this study revealed that one year after a single subcutaneous immunisation with influenza A H3N2 virus in an oil-based carrier, VaxcineTM, outbreed mice produced a high immunoglobulin G response that lasted for up to one year and exhibited less variation in titre compared with the response of the control group treated with alum. The haemagglutination-inhibition titres induced by VaxcineTM were also higher than those generated by alum. These data indicate that VaxcineTM is a good adjuvant candidate for seasonal influenza vaccines. |
| publishDate |
2011 |
| dc.date.none.fl_str_mv |
2011-12-01 |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000800026 |
| url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000800026 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
10.1590/S0074-02762011000800026 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
text/html |
| dc.publisher.none.fl_str_mv |
Instituto Oswaldo Cruz, Ministério da Saúde |
| publisher.none.fl_str_mv |
Instituto Oswaldo Cruz, Ministério da Saúde |
| dc.source.none.fl_str_mv |
Memórias do Instituto Oswaldo Cruz v.106 n.8 2011 reponame:Memórias do Instituto Oswaldo Cruz instname:Fundação Oswaldo Cruz instacron:FIOCRUZ |
| reponame_str |
Memórias do Instituto Oswaldo Cruz |
| collection |
Memórias do Instituto Oswaldo Cruz |
| instname_str |
Fundação Oswaldo Cruz |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| repository.name.fl_str_mv |
Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz |
| repository.mail.fl_str_mv |
|
| _version_ |
1669937710971748352 |